tradingkey.logo

Profound Medical Corp

PROF

4.340USD

+0.210+5.08%
Close 09/19, 16:00ETQuotes delayed by 15 min
130.43MMarket Cap
LossP/E TTM

Profound Medical Corp

4.340

+0.210+5.08%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
96 / 207
Overall Ranking
210 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 5 analysts
Buy
Current Rating
11.313
Target Price
+173.91%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 59.86% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 10.68M.
Overvalued
The company’s latest PE is -2.99, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 19.22M shares, increasing 8.94% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.38.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.15, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.21M, representing a year-over-year decrease of 0.99%, while its net profit experienced a year-over-year decrease of 126.84%.

Score

Industry at a Glance

Previous score
6.15
Change
0

Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

7.44

Operational Efficiency

2.77

Growth Potential

3.47

Shareholder Returns

7.09

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -2.84, which is 99.70% below the recent high of -5.68 and -149.22% above the recent low of -7.09.

Score

Industry at a Glance

Previous score
2.80
Change
1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 96/207
No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.80, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Profound Medical Corp is 11.12, with a high of 12.00 and a low of 11.00.

Score

Industry at a Glance

Previous score
8.80
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts
Buy
Current Rating
11.313
Target Price
+173.91%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

94
Total
4
Median
7
Average
Company name
Ratings
Analysts
Profound Medical Corp
PROF
5
Boston Scientific Corp
BSX
36
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
34
Veeva Systems Inc
VEEV
32
Thermo Fisher Scientific Inc
TMO
31
1
2
3
...
19

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.38, which is lower than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 4.72 and the support level at 3.65, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.38
Change
0.29

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(3)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
0.102
Neutral
RSI(14)
46.491
Neutral
STOCH(KDJ)(9,3,3)
68.728
Buy
ATR(14)
0.215
High Vlolatility
CCI(14)
58.714
Neutral
Williams %R
25.161
Buy
TRIX(12,20)
-0.989
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
4.114
Buy
MA10
4.063
Buy
MA20
4.273
Buy
MA50
4.988
Sell
MA100
5.276
Sell
MA200
5.954
Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score
5.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Gagnon (Neil)
3.35M
+531.45%
Fidelity Investments Canada ULC
1.81M
+1.11%
Gagnon Securities LLC
1.70M
+2.73%
BDC Venture Capital
1.22M
--
Letko, Brosseau & Associates Inc.
1.21M
-0.27%
Daseke Don R
1.10M
--
Gagnon Advisors, LLC
896.67K
--
Raymond James Financial Services Advisors, Inc.
828.37K
+1.77%
Timelo Investment Management Inc.
991.00K
+8.69%
Royce Investment Partners
Star Investors
761.80K
-0.39%
1
2

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.19, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.29. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.19
Change
0
Beta vs S&P 500 index
0.30
VaR
+6.11%
240-Day Maximum Drawdown
+56.81%
240-Day Volatility
+73.72%
Return
Best Daily Return
60 days
+11.76%
120 days
+17.39%
5 years
+29.04%
Worst Daily Return
60 days
-23.29%
120 days
-23.29%
5 years
-23.29%
Sharpe Ratio
60 days
-2.00
120 days
-0.99
5 years
-0.14
Risk Assessment
Maximum Drawdown
240 days
+56.81%
3 years
+73.99%
5 years
+88.68%
Return-to-Drawdown Ratio
240 days
-0.87
3 years
+0.04
5 years
-0.18
Skewness
240 days
-0.11
3 years
+0.73
5 years
+0.72
Volatility
Realised Volatility
240 days
+73.72%
5 years
+67.95%
Standardised True Range
240 days
+8.83%
5 years
+14.38%
Downside Risk-Adjusted Return
120 days
-129.14%
240 days
-129.14%
Maximum Daily Upside Volatility
60 days
+38.98%
Maximum Daily Downside Volatility
60 days
+53.00%
Liquidity
Average Turnover Rate
60 days
+0.26%
120 days
+0.26%
5 years
--
Turnover Deviation
20 days
+137.75%
60 days
+19.74%
120 days
+20.65%

Peer Comparison

Healthcare Equipment & Supplies
Profound Medical Corp
Profound Medical Corp
PROF
6.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
8.24 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
8.01 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI